Austin co. strikes deal with MD Anderson, adds to momentum in cancer fight
Genprex Inc. had a big week on Wall Street after sealing a deal with MD Anderson Cancer Center to advance research and development efforts. It was the latest piece of big news for a firm that has raised tens of millions of dollars in recent months, reshaped its C-suite and struck other major partnerships. The agreement means Genprex (Nasdaq: GNPX) will be able to test its most promising gene therapy, called Oncoprex, with a range of immunotherapies.
